Atossa Therapeutics Inc stock is traded at $1.99, with a volume of 1,488. It is down -1.49% in the last 24 hours and down -18.78% over the past month. Atossa Therapeutics Inc is a clinical-stage biopharmaceutical company engaged in the development of proprietary medicines for oncology, with a focus on breast cancer and related conditions. The company's lead product candidate, oral (Z)-endoxifen, is a selective estrogen receptor modulator and degrader (SERM/SERD) in Phase 2 clinical development, being evaluated for the treatment and prevention of breast cancer and other indications.
Previous Close:
$2.02
Open:
$1.99
24h Volume:
1,488
Relative Volume:
0.03
Market Cap:
$19.86M
Revenue:
-
Net Income/Loss:
-$37.64M
P/E Ratio:
-
EPS:
-$4.37
Net Cash Flow:
-$33.40M
1W Performance:
-8.29%
1M Performance:
-18.78%
6M Performance:
-65.69%
1Y Performance:
-83.71%
1-Day Range:
$1.99$1.99
1-Week Range:
$1.98$2.40
52-Week Range:
$1.70$14.85
Atossa Therapeutics Inc Stock (ATOS) Company Profile
Name
Atossa Therapeutics IncSector
HealthcareIndustry
BiotechnologyPhone
206.588.0256Address
1448 NW MARKET STREET, SEATTLE, WA, USAMarket Cap
Revenue
Net Income
Cash Flow
EPS